1. Валиев Т.Т., Ковригина А.М., Попа А.В., Левашов А.С., Менткевич Г.Л. Современные возможности диагностики и лечения диффузной В-крупноклеточной лимфомы у детей и взрослых (обзор литературы). Соврем. онкология. 2015; (3): 30–41.
Valiev T.T., Kovrigina A.M., Popa A.V., Levashov A.S., Mentkevich G.L. Modern possibilities of diagnostics and treatment of diffuse large b-cell lymphoma in children and adults (literature review). Sovremennaya onkologiya = Journal of Modern Oncology. 2015; (3): 30–41. [In Russian].
2. Дьяконов Д.А., Росин В.А., Ванеева Е.В., Самарина С.В. Способ морфометрической оценки прогноза течения диффузной В-крупноклеточной лимфомы по содержанию STAT3 опухолевых клеток в лимфатических узлах. Пат. 2694838 РФ; Опубл. 17.07.2019.
Dyakonov D.A, Rosin V.A., Vaneeva E.V., Samarina S.V. A method of morphometric assessment of the prognosis of diffuse B-large cell lymphoma by the content of STAT3 tumor cells in lymph nodes. Patent 2694838 RF; Published 17.07. 2019. [In Russian].
3. Поддубная И.В. Диффузная В-клеточная крупноклеточная лимфома. В кн.: Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Ред. И.В. Поддубная, В.Г. Савченко. М.: Буки Веди, 2018. 58–65.
Poddubnaya I.V. Diffuse large B-cell lymphoma. In: Russian clinical recommendations on diagnostics and treatment of lymphoproliferative disorders. Eds. I.V. Poddubnaya, V.G. Savchenko. Moscow: Buki Vedi, 2018. 58–65. [In Russian].
4. Расторгуев С.М., Королева Д.А., Булыгина Е.С. Цыганкова С.В., Гончаров Н.Г., Нарайкин О.С., Габеева Н.Г., Звонков Е.Е., Недолужко А.В. Клиническое и прогностическое значение молекулярных маркеров диффузной В-крупноклеточной лимфомы. Клин. онкогематология. 2019; 12 (1): 95–100. doi: 10.21320/2500-2139-2019-12-1-95-100.
Rastorguev S.M., Koroleva D.A., Bulygina E.S., Tsygankova S.V., Goncharov N.G., Naraykin O.S., Gabeeva N.G., Zvonkov E.E., Nedoluzhko A.V. Clinical and prognostic value of molecular markers of diffuse large B-cell lymphoma. Klinicheskaya onkogematologiya = Clinical Oncohematology. 2019; 12 (1): 95–100. [In Russian]. doi: 10.21320/2500-2139-2019-12-1-95-100.
5. Шапошников А.В., Комарьков И.Ф., Лебедева Л.А., Шидловский Ю.В. Строение сигнального пути JAK/STAT и его взаимосвязь с аппаратом транскрипции. Молекул. биология. 2013; 47 (3): 388–397. doi: 10.7868/s0026898413030130.
Shaposhnikov A.V., Komar’kov I.F., Lebedeva L.A., Shidlovskii Yu.V. Molecular components of JAK/STAT signaling pathway and its interaction with transcription machinery. Mol. Biol. 2013; 47 (3): 343–351. doi: 10.7868/s0026898413030130.
6. Aaronson D.S., Horvath C.M. A road map for those who don’t know JAK-STAT. Science. 2002; 296 (5573): 1653–1655. doi: 10.1126/science.1071545.
7. Adida C., Haioun C., Gaulard P., Lepage E., Morel P., Briere J., Dombret H., Reyes F., Diebold J., Gisselbrecht C., Salles G., Altieri D.C., Molina T.J. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000; 96 (5): 1921–1925.
8. Alizadeh A.A., Eisen M.B., Davis R.E. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000. 403: 503–511. doi: 10.1038/35000501.
9. Bastion Y., Blay J.Y., Divine M., Brice P., Bordessoule D., Sebban C., Blanc M., Tilly H., Lederlin P., Deconinck E., Salles B., Dumontet C., Briere J., Coiffier B. Elderly patients with aggressive non-Hodgkin’s lymphoma: disease presentation, response to treatment, and survival – a Groupe d’Etude des Lymphomes de l’Adulte study on 453 patients older than 69 years. J. Clin. Oncol. 1997; 15 (8): 2945–2953. doi: 10.1200/JCO.1997.15.8.2945.
10. Сabattini E., Pileri S.A., Dirnhofer S., Went P., Ascani S., Marafioti T., Tzankov A., Leoncini L., Falini B., Zinzani P.L. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology. 2002; 41 (6): 482–509. doi: 10.1046/j.1365-2559.2002.01538.x.
11. Darnell J.E. Validating Stat3 in cancer therapy. Nat. Med. 2005; 11: 595–596. doi: 10.1038/nm0605-595.
12. Ding B.B., Yu J.J., Yu R.Y., Mendez L.M., Shaknovich R., Zhang Y., Cattoretti G., Ye B.H. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008; 111 (3): 1515–1523. doi: 10.1182/blood-2007-04-08773.doi: 10.1182/blood-2007-04-087734.
13. Gomez H., Mas L., Casanova L., Pen D.L., Santillana S., Valdivia S., Otero J., Rodriguez W., Carracedo C., Vallejos C. Elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J. Clin. Oncol. 1998; 16 (7): 2352–2358. doi: 10.1200/JCO.1998.16.7.2352.
14. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., Muller Hermelink H.K., Campo E., Braziel R.M., Jaffe E.S., Pan Z., Farinha P., Smith L.M., Falini B., Banham A.H., Rosenwald A., Staudt L.M., Connors J.M., Armitage J.O., Chan W.C. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103 (1): 275–282. doi: 10.1182/blood-2003-05-1545.
15. Huang X., Meng B., Iqbal J., Ding B.B., Perry A.M., Cao W., Smith L.M., Bi C., Jiang C., Greiner T.C., Weisenburger D.D., Rimsza L., Rosenwald A., Ott G., Delabie J., Campo E., Braziel R.M., Gascoyne R.D., Cook J.R., Tubbs R.R., Jaffe E.S., Armitage J.O., Vose J.M., Staudt L.M., McKeithan T.W., Chan W.C., Ye B.H., Fu K. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J. Clin. Oncol. 2013; 31 (36): 4520-4528. doi: 10.1200/JCO.2012.45.6004
16. Lam L.T., Wright G., Davis R.E. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008; 111: 3701–3713. doi: 10.1182/blood-2007-09-111948.
17. Lin S., Yujun L., Xiaoming X., Wenwen R. Expression and significance of leptin receptor, p-STAT3 and p-AKT in diffuse large B-cell lymphoma. Acta Histochem. 2014; 116: 126–130. doi: 10.1016/j.acthis.2013.06.003.
18. Liu H., Zhu L., Sun C., Xie W., Qian W., Ye X. Clinical significance and prognostic value of STAT3 expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Int. J. Clin. Exp. Med. 2016; 9 (6): 9356–9364.
19. Meyer P.N., Fu K., Greiner T.C., Smith L.M., Delabie J., Gascoyne R.D., Ott G., Rosenwald A., Braziel R.M., Campo E., Vose J.M., Lenz G., Staudt L.M., Chan W.C., Weisenburger D.D. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J. Clin. Oncol. 2011; 29 (2): 200–207. doi: 10.1200/JCO.2010.30.0368.
20. Morgensztern D., Lossos I.S. Molecular prognostic factors in diffuse large B-cell lymphoma. Curr. Treat. Options Oncol. 2005; 6 (4): 269–277.
21. Ok C.Y., Chen J., Xu-Monette Z.Y., Tzankov A., Manyam G.C., Li L., Visco C., Montes-Moreno S., Dybkaer K., Chiu A., Orazi A., Zu Y., Bhagat G., Richards K.L., Hsi E.D., Choi W.W., van Krieken J.H., Huh J., Zhao X., Ponzoni M., Ferreri A.J., Bertoni F., Farnen J.P., Moller M.B., Piris M.A., Winter J.N., Medeiros L.J., Young K.H. Clinical implications of phosphorylated STAT3 expression in de novo diffuse large B-cell lymphoma. Clin. Cancer Res. 2014; 20 (19): 5113–5123. doi: 10.1158/1078-0432.CCR-14-0683.
22. Ok C.Y., Chen J., Xu-Monette Z.Y., Tzankov A., Visco C., Chiu A., Orazi A., Zu Y., Bhagat G., Richards K.L., Hsi E.D., Choi W.W., van Krieken J.H., Ponzoni M., Ferreri A.J., Farnen J.P., Moller M.B., Winter J.N., Piris M.A., Medeiros L.J., Young K.H. STAT3 expressions and clinical inplications in de Novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013; 122: 365.
23. Rawlings J.S., Rosler K.M., Harrison D.A. The JAK/STAT signaling pathway. J. Cell Sci. 2004; 117 (8): 1281–1283. doi: 10.1242/jcs.00963.
24. Rosenwald A., Wright G., Chan W.C. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346 (25): 1937–1947. doi: 10.1056/NEJMoa012914.
25. Sehn L.H., Gascoyn R.D. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015; 125 (1): 22–32. doi: 10.1182/blood-2014-05-577189.
26. Shipp M.A., Ross K.N., Tamayo P. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 2002; 8: 68–74. doi: 10.1038/nm0102-68.
27. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th Edition. Eds. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele. Geneva: WHO Press, 2017. 585 p.
28. Wu Z.L., Song Y.Q., Shi Y.F., Zhu J. High nuclear expressions of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J. Hematol. Oncol. 2011; 4 (31): 1–6. doi: 10.1186/1756-8722-4-31.
29. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer. 2009; 9 (11): 798–809. doi: 10.1038/nrc2734.